Blog

RSS Feed
Posted by Michael Wonder on 11 Jul 2020

How can cancer drug prices better match their benefits? Germany offers a cost-saving model

10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...

Read more →
Posted by Michael Wonder on 20 May 2019

Europe responding to gene therapy challenge, but picture remains fragmented

20 May 2019 - Germany, Italy and England using outcomes-based deals. ...

Read more →
Posted by Michael Wonder on 05 Mar 2019

Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany

5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...

Read more →
Posted by Michael Wonder on 10 Oct 2018

New drugs: how much are governments paying for innovation?

10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments. ...

Read more →
Posted by Michael Wonder on 27 Apr 2018

IQWiG in dialogue on 15 June 2018: Do the new "estimand" strategies threaten the standards of benefit assessment?

26 April 2018 - Registration now possible/discussion about current method proposals of the EMA. ...

Read more →
Posted by Michael Wonder on 09 Sep 2017

Can a new value framework help ease friction over orphan drug prices?

7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...

Read more →